Perspectum Ltd’s Post

Part of Secondary Prevention in my eyes = Early accurate Multi-organ Clinical assessment (Opportunity) & Diagnostics ... to enable Early and efficacious Multi-organ Disease Management...

🔍 New Data on REBOA: Partial vs Complete – Which is Better? 🏥 From EVTM a recent study from the AAST AORTA registry challenges preclinical expectations, showing no significant differences in mortality or complications between partial and complete REBOA in trauma patients. But the debate isn’t over yet! 🧐 Incomplete data and the need for larger sample sizes make it hard to draw definitive conclusions. What will future studies reveal? 🔗 Learn more about REBOA’s effectiveness in trauma care and what’s needed to unlock its true potential! https://lnkd.in/drDdz-A2

Understanding the value of multi-omics DDW’s Megan Thomas discusses the opportunity in the multi-omics sector by speaking with leading players and looking at the ways in which it can help us tackle disease. https://lnkd.in/eA4jnfxM #Multiomics #DrugDiscovery #Omics

Don't miss out! EDUCARE Deep Dive Sessions at #LINC2024 Gain expert insights into different areas of vascular disease – and how to optimize their treatment. Deep dive sessions: - Integrating diagnostic and therapeutic tools for the effective management of PAD. Acute Limb Ischaemia and Critical Limb Ischaemia focuses - Prof. Torsello, and Dr. Stavroulakis, Germany. - Unlock the Potential of IVUS Imaging: an expert's perspective. Arterial IVUS focuses - Prof. Torsello, Germany and Dr. Alvarez, Spain. Venous IVUS and Aortic IVUS focuses - Prof. Lugli, Italy. Reserve your session here: https://lnkd.in/d_PyUrSA #ClinicalEvidence #BSCEMEA #EndovascularCare #Innovation #MedicalEducation #arterialinterventions

Today is Global ALS/MND Awareness Day 2024. ALS is the most common form of motor neuron disease (MND) and causes a rapidly progressing, devastating loss of muscle control. Sadly, there's currently no cure and only limited therapies that aim to ease symptoms and prolong life, usually by just a few months. We're proud to be working towards better ALS therapies and would like to thank our generous patient donors who have enabled us to develop our axoLines™ ALS cell lines. Take a look at our Focus on ALS document to learn about how we're using human iPSC technology to build better ALS models for research and drug discovery: https://hubs.la/Q02CMV-30 #iPSCs #ALS #ALSAwarenessDay #ALSMNDWithoutBorders

Today is Global ALS/MND Awareness Day 2024. ALS is the most common form of motor neuron disease (MND) and causes a rapidly progressing, devastating loss of muscle control. Sadly, there's currently no cure and only limited therapies that aim to ease symptoms and prolong life, usually by just a few months. We're proud to be working towards better ALS therapies and would like to thank our generous patient donors who have enabled us to develop our axoLines™ ALS cell lines. Take a look at our Focus on ALS document to learn about how we're using human iPSC technology to build better ALS models for research and drug discovery: https://hubs.la/Q02CMVsk0 #iPSCs #ALS #ALSAwarenessDay #ALSMNDWithoutBorders

In the face of VUS, patients confront not just genetic uncertainties but emotional and mental hurdles too—highlighting the urgency for clarity and action in genetic diagnosis. Transforming uncertainty into precision, one variant at a time with MAVEvidence, the premier functional evidence resource. Dive into our vast database of over 186,000 pieces of evidence across 124,000 variants for precise, up-to-date insights. #vus #MAVEvidence #patientcare #genetictesting

City Imaging Responds to a Call for Early Screening of Liver Diseases with Launch and Extension of FibroScan, Dr. Aakaar Kapoor, Founder & Partner - City Imaging & Clinical Labs, shared his views on the topic with The Pharma Times. Click Here To Read More:- https://lnkd.in/g9hFYwkA #FibroScan #Launch #LiverDiseases #Healthsector #Healthnews #ThePharmaTimes #NewsMedia #Cityimaging #MediaPublishing #NewsArticles

Detecting #liver lesions is the initial step in the diagnostic process. However, equally crucial is the subsequent characterization phase. Is it a benign cyst, a hemangioma, or possibly metastatic disease? How often do uncertainties arise in your assessments? How many follow-up examinations do you find necessary? And what level of uncertainty is inherent in your scanning technology? We were curious to find out! That's why we developed the world's first #classification #phantom featuring three common types of liver lesions: cysts, hemangiomas, and metastases. Explore firsthand how scanner technologies impact lesion morphology and confidence in lesion #characterization. Have questions? Reach out to us at info@phantomx.de or visit our website www.phantomx.de.

Check out this interesting article from 360Dx below on a biomarker study that Thermo Fisher Scientific is participating in with the FNIH in the hopes to make strides in the early detection of preeclampsia.